science
Roche Halts Two Huntington’s Gene-Silencing Drug Programs
Roche stopped development of two Huntington’s disease treatments after new data did not support further testing. ARPA-H separately announced a $160 million program for custom gene-editing therapies for rare diseases.
Jul 10, 9:47 AM·1m read1 source
swissinfo.chAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Roche ended two Huntington’s disease gene-silencing drug programs after new data failed to support continued testing. The company notified patient advocates by letter of the decision.
ARPA-H announced a $160 million program aimed at developing custom gene-editing therapies for rare diseases. The agency said the effort is intended to accelerate such treatments into clinical use. Drugmakers also agreed to promote Medicare’s new obesity drug discount program, according to the same report.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationLimited · 1 source
